

OK TO ENTER: /TM/ (08/26/2009)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

| | | | |
|-----------------|--|---------------------|---|
| Application of: | LaColla <i>et al.</i> | Confirmation No.: | 9201 |
| Serial No.: | 10/609,298 | Art Unit: | 1623 |
| Filed: | June 27, 2003 | Examiner: | T. McIntosh III |
| For: | 2' AND 3' NUCLEOSIDE PRODRUGS FOR TREATING FLAVIVIRIDAE INFECTIONS | Attorney Docket No: | 11874-016-999 (CAM: 417451-999016) IDX 1017 |

AMENDMENT AFTER ALLOWANCE UNDER 37 C.F.R. § 1.312

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The following amendment supplements the amendment filed on January 8, 2009 in response to the Office Action of July 10, 2008. Submitted concurrently herewith is a Petition under 37 C.F. R. § 1.182, along with the petition fee set forth in 37 C.F.R. § 1.17(f).

Pursuant to 37 C.F.R. § 1.312, Applicants respectfully request entry of the following amendments and remarks without withdrawing the application from issue.

Pursuant to 37 C.F.R. § 1.71(g)(2), the processing fee set forth in 37 C.F.R. § 1.17(i) for the amendment to the specification will be paid via EFS Web.

Amendments to the Specification begin on page 2.

Remarks begin on page 3.